Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about AMGEN
12/15 AMGEN : Announces 15 Percent Increase in 2018 First Quarter Dividend
12/15 AMGEN : Foundation Pledges Up To $500,000 in Relief to Victims of the Southern C..
12/15 AMGEN : KYPROLIS Extended Overall Survival in Patients with Relapsed or Refracto..
12/14 AMGEN : Teams Up With Cambridge Biotech Community To Select Two Startups To Rece..
12/12 AMGEN : Announces 15 Percent Increase In 2018 First Quarter Dividend
12/12 AMGEN : Dutch NASH play NorthSea debuts with EUR 25M
12/11 AMGEN : KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relap..
12/11 AMGEN : Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern C..
12/11 AMGEN : New Data to Be Presented at ASH 2017 Underscore Amgen's Commitment to Im..
12/08 AMGEN : to Webcast Investor Call at ASH 2017
12/07 AMGEN : New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Im..
12/06 AMGEN : To Webcast Investor Call At ASH 2017
12/05 Value-based models a driver of CVS-Aetna deal
12/04 AMGEN : Three Huge Biotech Companies Just Scored Three Huge Drug Approvals In Th..
12/04 BIOCARTIS GROUP NV : Biocartis and Amgen Sign Companion Diagnostic Agreement for..
More most relevant news
All news about AMGEN
12/15 AMGEN : Announces 15 Percent Increase in 2018 First Quarter Dividend
12/15 AMGEN : Foundation Pledges Up To $500,000 in Relief to Victims of the Southern C..
12/15 AMGEN : KYPROLIS Extended Overall Survival in Patients with Relapsed or Refracto..
12/14 AMGEN : Teams Up With Cambridge Biotech Community To Select Two Startups To Rece..
12/14 AMGEN : FDA Approves Amgen's Repatha® evolocumab To Prevent Heart Attack And Str..
12/14 AMGEN : Researchers at Amgen Detail Findings in Immunoglobulins (Identification ..
12/14 AMGEN : New Findings from Amgen in Biotechnology Provides New Insights (Mechanis..
12/12 AMGEN : Announces 15 Percent Increase In 2018 First Quarter Dividend
12/12 AMGEN : Dutch NASH play NorthSea debuts with EUR 25M
12/11 AMGEN : KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relap..
More news
Sector news : Pharmaceuticals - NEC
12/17 TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
12/16 NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/16 PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/16 BiTE Amgen For Long-Term Returns
12/15 Premarket analyst action - healthcare
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Why Tech Still Looks So Attractive
12/12 Amgen declares $1.32 dividend
Financials ($)
Sales 2017 22 886 M
EBIT 2017 11 755 M
Net income 2017 8 326 M
Finance 2017 6 819 M
Yield 2017 2,55%
P/E ratio 2017 15,73
P/E ratio 2018 15,67
EV / Sales 2017 5,32x
EV / Sales 2018 5,13x
Capitalization 129 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 191 $
Spread / Average Target 7,6%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN21.32%128 515
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386